<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37029295</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Scientific rationale for the use of &#x3b1;2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders.</ArticleTitle><Pagination><StartPage>4540</StartPage><EndPage>4552</EndPage><MedlinePgn>4540-4552</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-023-02057-4</ELocationID><Abstract><AbstractText>Neuroinflammatory disorders preferentially impair the higher cognitive and executive functions of the prefrontal cortex (PFC). This includes such challenging disorders as delirium, perioperative neurocognitive disorder, and the sustained cognitive deficits from "long-COVID" or traumatic brain injury. There are no FDA-approved treatments for these symptoms; thus, understanding their etiology is important for generating therapeutic strategies. The current review describes the molecular rationale for why PFC circuits are especially vulnerable to inflammation, and how &#x3b1;2A-adrenoceptor (&#x3b1;2A-AR) actions throughout the nervous and immune systems can benefit the circuits in PFC needed for higher cognition. The layer III circuits in the dorsolateral PFC (dlPFC) that generate and sustain the mental representations needed for higher cognition have unusual neurotransmission and neuromodulation. They are wholly dependent on NMDAR neurotransmission, with little AMPAR contribution, and thus are especially vulnerable to kynurenic acid inflammatory signaling which blocks NMDAR. Layer III dlPFC spines also have unusual neuromodulation, with cAMP magnification of calcium signaling in spines, which opens nearby potassium channels to rapidly weaken connectivity and reduce neuronal firing. This process must be tightly regulated, e.g. by mGluR3 or &#x3b1;2A-AR on spines, to prevent loss of firing. However, the production of GCPII inflammatory signaling reduces mGluR3 actions and markedly diminishes dlPFC network firing. Both basic and clinical studies show that &#x3b1;2A-AR agonists such as guanfacine can restore dlPFC network firing and cognitive function, through direct actions in the dlPFC, but also by reducing the activity of stress-related circuits, e.g. in the locus coeruleus and amygdala, and by having anti-inflammatory actions in the immune system. This information is particularly timely, as guanfacine is currently the focus of large clinical trials for the treatment of delirium, and in open label studies for the treatment of cognitive deficits from long-COVID.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arnsten</LastName><ForeName>Amy F T</ForeName><Initials>AFT</Initials><Identifier Source="ORCID">0000-0002-3420-1308</Identifier><AffiliationInfo><Affiliation>Department Neuroscience, Yale University School of Medicine, New Haven, CT, 056510, USA. amy.arnsten@yale.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishizawa</LastName><ForeName>Yumiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department Anesthesiology, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zhongcong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department Anesthesiology, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG061190</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041274</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>30OMY4G3MK</RegistryNumber><NameOfSubstance UI="D016316">Guanfacine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C547768">ADRA2A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="Y">Delirium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016316" MajorTopicYN="N">Guanfacine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>7</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37029295</ArticleId><ArticleId IdType="pmc">PMC10080530</ArticleId><ArticleId IdType="doi">10.1038/s41380-023-02057-4</ArticleId><ArticleId IdType="pii">10.1038/s41380-023-02057-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kirova AM, Bays RB, Lagalwar S. Working memory and executive function decline across normal aging, mild cognitive impairment, and Alzheimer&#x2019;s disease. Biomed Res Int. 2015;2015:748212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624908</ArticleId><ArticleId IdType="pubmed">26550575</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald B, Flashman L, Saykin AJ. Executive dysfunction following traumatic brain injury: neural substrates and treatment strategies. NeuroRehabilitation. 2002;17:33&#x2013;44..</Citation><ArticleIdList><ArticleId IdType="pubmed">12547981</ArticleId></ArticleIdList></Reference><Reference><Citation>Rundshagen I. Postoperative cognitive dysfunction. Dtsch Arztebl Int. 2014;111:119&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959222</ArticleId><ArticleId IdType="pubmed">24622758</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczepanski SM, Knight RT. Insights into human behavior from lesions to the prefrontal cortex. Neuron. 2014;83:1002&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4156912</ArticleId><ArticleId IdType="pubmed">25175878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmuth J, Barnett TA, Asken BM, Kelly JD, Torres L, Stephens ML, et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. J Neurovirol. 2021;27:191&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852463</ArticleId><ArticleId IdType="pubmed">33528824</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Datta D, Wang M. The Genie in the Bottle- Magnified calcium signaling in dorsolateral prefrontal cortex. Mol Psychiatry. 2021;26:3684&#x2013;3700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8203737</ArticleId><ArticleId IdType="pubmed">33319854</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT. Guanfacine&#x2019;s mechanism of action in treating prefrontal cortical disorders: Successful translation across species. Neurobiol Learn Mem. 2020;176:107327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567669</ArticleId><ArticleId IdType="pubmed">33075480</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;thert M. Role of autoreceptors in the function of the peripheral and central nervous system. Arzneimittelforschung. 1985;35:1909&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">3006707</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman-Rakic PS. Circuitry of the primate prefrontal cortex and the regulation of behavior by representational memory. In: Plum F, editor. Handbook of Physiology, The Nervous System, Higher Functions of the Brain, vol. V. Bethesda MD, USA: American Physiological Society, 1987, pp 373&#x2013;417.</Citation></Reference><Reference><Citation>Ong&#xfc;r D, Price JL. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cereb Cortex. 2000;10:206&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">10731217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise SP. Forward frontal fields: phylogeny and fundamental function. Trends Neurosci. 2008;31:599&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587508</ArticleId><ArticleId IdType="pubmed">18835649</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce MK, Garcia-Cabezas MA, John Y, Barbas H. Serial prefrontal pathways are positioned to balance cognition and emotion in primates. J Neurosci. 2020;40:8306&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577604</ArticleId><ArticleId IdType="pubmed">32989097</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman-Rakic P. Cellular Basis of Working Memory. Neuron. 1995;14:477&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695894</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Cools R. Neuromodulation of prefrontal cortex cognitive function in primates: The powerful roles of monoamines and acetylcholine. Neuropsychopharmacology. 2022;47:309&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8617291</ArticleId><ArticleId IdType="pubmed">34312496</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsujimoto S, Genovesio A, Wise SP. Frontal pole cortex: encoding ends at the end of the endbrain. Trends Cogn Sci. 2011;15:169&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">21388858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wylie GR, Pra Sisto AJ, Genova HM, DeLuca J. Fatigue Across the Lifespan in Men and Women: State vs. Trait. Front Hum Neurosci. 2022;16:790006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9124897</ArticleId><ArticleId IdType="pubmed">35615746</ArticleId></ArticleIdList></Reference><Reference><Citation>Aupperle RL, Allard CB, Grimes EM, Simmons AN, Flagan T, Behrooznia M, et al. Dorsolateral prefrontal cortex activation during emotional anticipation and neuropsychological performance in posttraumatic stress disorder. Arch Gen Psychiatry. 2012;69:360&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">22474105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha R, Lacadie CM, Constable RT, Seo D. Dynamic neural activity during stress signals resilient coping. Proc Natl Acad Sci USA. 2016;113:8837&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978278</ArticleId><ArticleId IdType="pubmed">27432990</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10:1529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449365</ArticleId><ArticleId IdType="pubmed">30948709</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoskison MM, Moore AN, Hu B, Orsi SA, Kobori N, Dash PK. Persistent working memory dysfunction following traumatic brain injury: evidence for a time-dependent mechanism. Neuroscience. 2009;159:483&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264540</ArticleId><ArticleId IdType="pubmed">19167462</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash PK, Johnson D, Clark J, Orsi SA, Zhang M, Zhao J, et al. Involvement of the glycogen synthase kinase-3 signaling pathway in TBI pathology and neurocognitive outcome. PLoS One. 2011;6:e24648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174188</ArticleId><ArticleId IdType="pubmed">21935433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobori N, Hu B, Dash PK. Altered adrenergic receptor signaling following traumatic brain injury contributes to working memory dysfunction. Neuroscience. 2011;172:293&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010433</ArticleId><ArticleId IdType="pubmed">20974230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobori N, Moore AN, Dash PK. Altered regulation of protein kinase a activity in the medial prefrontal cortex of normal and brain-injured animals actively engaged in a working memory task. J Neurotrauma. 2015;32:139&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4291093</ArticleId><ArticleId IdType="pubmed">25027811</ArticleId></ArticleIdList></Reference><Reference><Citation>Inouye SK. Delirium in Older Persons. N. Engl J Med. 2006;354:1157&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16540616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylvisaker M, Feeney TJ. Executive functions after traumatic brain injury: supported cognition and self-advocacy. Semin Speech Lang. 1996;17:217&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8912437</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllister TW, Flashman LA, Sparling MB, Saykin AJ. Working memory deficits after traumatic brain injury: catecholaminergic mechanisms and prospects for treatment - a review. Brain Inj. 2004;18:331&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">14742148</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin HS, Hanten G. Executive functions after traumatic brain injury in children. Pediatr Neurol. 2005;33:79&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">15876523</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohnen N, Twijnstra A, Jolles J. Performance in the Stroop color word test in relationship to the persistence of symptoms following mild head injury. Acta Neurol Scand. 1992;85:116&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">1574984</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein MB, Jain S, Giacino JT, Levin H, Dikmen S, Nelson LD, et al. Risk of Posttraumatic Stress Disorder and Major Depression in Civilian Patients After Mild Traumatic Brain Injury: A TRACK-TBI Study. JAMA Psychiatry. 2019;76:249&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439818</ArticleId><ArticleId IdType="pubmed">30698636</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesharaki-Zadeh A, Miyauchi JT, St Laurent-Arriot K, Tsirka SE, Bergold PJ. Increased Behavioral Deficits and Inflammation in a Mouse Model of Co-Morbid Traumatic Brain Injury and Post-Traumatic Stress Disorder. ASN Neuro. 2020;12:1759091420979567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755938</ArticleId><ArticleId IdType="pubmed">33342261</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern RA, Riley DO, Daneshvar DH, Nowinski CJ, Cantu RC, McKee AC. Long-term consequences of repetitive brain trauma: chronic traumatic encephalopathy. PMR. 2011;3:S460&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">22035690</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, Alvarez VE, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136:43&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Moller JT, Cluitmans P, Rasmussen LS. ISPOCD investigators ISoP-OCD. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. Lancet. 1998;351:857&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9525362</ArticleId></ArticleIdList></Reference><Reference><Citation>Vutskits L, Xie Z. Lasting impact of general anaesthesia on the brain: mechanisms and relevance. Nat Rev Neurosci. 2016;17:705&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">27752068</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene NH, Attix DK, Weldon BC, Smith PJ, McDonagh DL, Monk TG. Measures of executive function and depression identify patients at risk for postoperative delirium. Anesthesiology. 2009;110:788&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953946</ArticleId><ArticleId IdType="pubmed">19326494</ArticleId></ArticleIdList></Reference><Reference><Citation>Mashour GA, Palanca BJ, Basner M, Li D, Wang W, Blain-Moraes S, et al. Recovery of consciousness and cognition after general anesthesia in humans. Elife. 2021;10:e59525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8163502</ArticleId><ArticleId IdType="pubmed">33970101</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter MG, Mincer JS, Brallier JW, Schwartz AB, Ahn H, Nir T, et al. Cognitive Recovery by Decade in Healthy 40- to 80-Year-Old Volunteers After Anesthesia Without Surgery. Anesth Analg. 2022;134:389&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8760160</ArticleId><ArticleId IdType="pubmed">34889804</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee NNM, Wilson FC, Curran DB, Lyttle N, McCann JP. Neurocognitive outcomes in adults following cerebral hypoxia: A systematic literature review. NeuroRehabilitation. 2020;47:83&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">32716324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Cui L, Ji X. Cognitive impairment caused by hypoxia: from clinical evidences to molecular mechanisms. Metab Brain Dis. 2022;37:51&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">34618295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauser H, Sahu S, Kumar S, Panjwani U. Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive decline. Neuroscience. 2013;254:110&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24056194</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderlind WM, Rabinovitz BB, Miao IY, Oberlin LE, Bueno-Castellano C, Fridman C, et al. A systematic review of neuropsychological and psychiatric sequalae of COVID-19: implications for treatment. Curr Opin Psychiatry. 2021;4:420&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183238</ArticleId><ArticleId IdType="pubmed">34016818</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, et al. Assessment of Cognitive Function in Patients After COVID-19 Infection. JAMA Netw Open. 2021;4:e2130645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536953</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A, Trender W, Chamberlain SR, Jolly AE, Grant JE, Patrick F, et al. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021;39:101044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8298139</ArticleId><ArticleId IdType="pubmed">34316551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayhurst CJ, Pandharipande PP, Hughes CG. Intensive Care Unit Delirium: A Review of Diagnosis, Prevention, and Treatment. Anesthesiology. 2016;125:1229&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119532</ArticleId><ArticleId IdType="pubmed">27748656</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrarini C, Russo M, Dono F, Barbone F, Rispoli MG, Ferri L, et al. Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions. Front Neurol. 2021;12:644317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8085397</ArticleId><ArticleId IdType="pubmed">33935943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Gamo NJ, Yang Y, Jin LE, Wang XJ, Laubach M, et al. Neuronal basis of age-related working memory decline. Nature. 2011;476:210&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193794</ArticleId><ArticleId IdType="pubmed">21796118</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta D, Leslie SN, Morozov YM, Duque A, Rakic P, van Dyck CH, et al. Classical complement cascade initiating C1q protein within neurons in the aged rhesus macaque dorsolateral prefrontal cortex. J Neuroinflammation. 2020;17:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6945481</ArticleId><ArticleId IdType="pubmed">31906973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Yang Y, Wang CJ, Gamo NJ, Jin LE, Mazer JA, et al. NMDA receptors subserve working memory persistent neuronal firing In dorsolateral prefrontal cortex. Neuron. 2013;77:736&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3584418</ArticleId><ArticleId IdType="pubmed">23439125</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Paspalas CD, Jin LE, Picciotto MR, Arnsten AFT, Wang M. Nicotinic &#x3b1;7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex. Proc Nat Acad Sci USA. 2013;110:12078&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718126</ArticleId><ArticleId IdType="pubmed">23818597</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaac JT, Nicoll RA, Malenka RC. Evidence for silent synapses: implications for the expression of LTP. Neuron. 1995;15:427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">7646894</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang ST, Wang M, Paspalas CP, Crimins JL, Altman MT, Mazer JA, et al. Core differences in synaptic signaling between primary visual and dorsolateral prefrontal cortex. Cereb Cortex. 2018;28:1458&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6041807</ArticleId><ArticleId IdType="pubmed">29351585</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoblenick K, Everling S. NMDA antagonist ketamine reduces task selectivity in macaque dorsolateral prefrontal neurons and impairs performance of randomly interleaved prosaccades and antisaccades. J Neurosci. 2012;32:12018&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621508</ArticleId><ArticleId IdType="pubmed">22933786</ArticleId></ArticleIdList></Reference><Reference><Citation>Driesen NR, McCarthy G, Bhagwagar Z, Bloch MH, Calhoun VD, D&#x2019;Souza DC, et al. The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology. 2013;38:2613&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3828532</ArticleId><ArticleId IdType="pubmed">23856634</ArticleId></ArticleIdList></Reference><Reference><Citation>Croxson PL, Kyriazis DA, Baxter MG. Cholinergic modulation of a specific memory function of prefrontal cortex. Nat Neurosci. 2011;14:1510&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3432567</ArticleId><ArticleId IdType="pubmed">22057191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim CK, Yap MM, Kent SJ, Gras G, Samah B, Batten JC, et al. Characterization of the kynurenine pathway and quinolinic Acid production in macaque macrophages. Int J Tryptophan Res. 2013;6:7&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662399</ArticleId><ArticleId IdType="pubmed">23761975</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrison AM, Parrott JM, Tu&#xf1;on A, Delgado J, Redus L, O&#x2019;Connor JC. Kynurenine pathway metabolic balance influences microglia activity: Targeting kynurenine monooxygenase to dampen neuroinflammation. Psychoneuroendocrinology. 2018;94:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5995655</ArticleId><ArticleId IdType="pubmed">29734055</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25:131&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6790159</ArticleId><ArticleId IdType="pubmed">30980044</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56:2007&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">1827495</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13:465&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681811</ArticleId><ArticleId IdType="pubmed">22678511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T, et al. Reduction of brain kynurenic acid improves cognitive function. J Neurosci. 2014;34:10592&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802596</ArticleId><ArticleId IdType="pubmed">25100593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kepplinger B, Baran H, Kainz A, Ferraz-Leite H, Newcombe J, Kalina P. Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2-microglobulin changes. Neurosignals. 2005;14:126&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">16088227</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight. 2020;5:e140327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453907</ArticleId><ArticleId IdType="pubmed">32559180</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Kim DJ, Takahashi T, Broadhurst DI, Yan H, Ma S, et al. Kynurenic acid may underlie sex-specific immune responses to COVID-19. Sci Signal. 2021;14:eabf8483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8432948</ArticleId><ArticleId IdType="pubmed">34230210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler NG, Gray N, Kimhofer T, Boughton B, Gay M, Yang R, et al. Systemic Perturbations in Amine and Kynurenine Metabolism Associated with Acute SARS-CoV-2 Infection and Inflammatory Cytokine Responses. J Proteome Res. 2021;20:2796&#x2013;2711..</Citation><ArticleIdList><ArticleId IdType="pubmed">33724837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cysique LA, Jakabek D, Bracken SG, Allen-Davidian Y, Heng B, Chow S, et al. Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study. medRxiv. 2022. 10.1101/2022.06.07.22276020.</Citation></Reference><Reference><Citation>Reiken S, Sittenfeld L, Dridi H, Liu Y, Liu X, Marks AR. Alzheimer&#x2019;s-like signaling in brains of COVID-19 patients. Alzheimers Dement. 2022;18:955&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011576</ArticleId><ArticleId IdType="pubmed">35112786</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams Wilson JR, Morandi A, Girard TD, Thompson JL, Boomershine CS, Shintani AK, et al. The association of the kynurenine pathway of tryptophan metabolism with acute brain dysfunction during critical illness. Crit Care Med. 2012;40:835&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625666</ArticleId><ArticleId IdType="pubmed">22080637</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest CM, Mackay GM, Oxford L, Millar K, Darlington LG, Higgins MJ, et al. Kynurenine metabolism predicts cognitive function in patients following cardiac bypass and thoracic surgery. J Neurochem. 2011;119:136&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">21819405</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier TB, Savitz J. The Kynurenine Pathway in Traumatic Brain Injury: Implications for Psychiatric Outcomes. Biol Psychiatry. 2022;91:449&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8630076</ArticleId><ArticleId IdType="pubmed">34266671</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan EB, Frugier T, Lim CK, Heng B, Sundaram G, Tan M, et al. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans. J Neuroinflammation. 2015;12:110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457980</ArticleId><ArticleId IdType="pubmed">26025142</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Ramos B, Paspalas C, Shu Y, Simen A, Duque A, et al. Alpha2A-adrenoceptor stimulation strengthens working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129:397&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448997</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, El-Hassar L, Datta D, Thomas M, Zhang Y, David PJ, et al. Interaction Between HCN and Slack Channels Regulates mPFC Pyramidal Cell Excitability and Working Memory. bioRxiv. 2023. https://www.biorxiv.org/content/10.1101/2023.03.04.529157v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.04.529157v1</ArticleId><ArticleId IdType="pubmed">37889366</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Jin LE, Gamo NJ, Ramos B, Paspalas CD, Morozov Y, et al. Role of KCNQ potassium channels in stress-induced deficit of working memory. Neurobio Stress. 2019;11:100187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6889760</ArticleId><ArticleId IdType="pubmed">31832507</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin VC, Yang S-T, Paspalas CD, Yang Y, Jin LE, Datta D, et al. Muscarinic M1 receptors modulate working memory performance and activity via KCNQ potassium channels in primate prefrontal cortex. Neuron. 2020;106:649&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7244366</ArticleId><ArticleId IdType="pubmed">32197063</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel T, Nguyen PV, Barad M, Deuel TA, Kandel ER, Bourtchouladze R. Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. Cell. 1997;88:615&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9054501</ArticleId></ArticleIdList></Reference><Reference><Citation>Havekes R, Park AJ, Tolentino RE, Bruinenberg VM, Tudor JC, Lee Y, et al. Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory. J Neurosci. 2016;36:8936&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995304</ArticleId><ArticleId IdType="pubmed">27559174</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Wang M, Paspalas CD. Neuromodulation of thought: Flexibilities and vulnerabilities in prefrontal cortical network synapses. Neuron. 2012;76:223&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3488343</ArticleId><ArticleId IdType="pubmed">23040817</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT. Stress signaling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009;10:410&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907136</ArticleId><ArticleId IdType="pubmed">19455173</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta D, Arnsten AFT. Loss of Prefrontal Cortical Higher Cognition with Uncontrollable Stress: Molecular Mechanisms, Changes with Age, and Relevance to Treatment. Brain Sci. 2019;9:113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6562841</ArticleId><ArticleId IdType="pubmed">31108855</ArticleId></ArticleIdList></Reference><Reference><Citation>Finlay JM, Zigmond MJ, Abercrombie ED. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neuroscience. 1995;64:619&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715775</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LE, Rasmusson AM, Bunney SB, Roth RH. Role of the amygdala in the coordination of behavioral, neuroendocrine and prefrontal cortical monoamine responses to psychological stress in the rat. J Neurosci. 1996;16:4787&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579011</ArticleId><ArticleId IdType="pubmed">8764665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobori N, Clifton GL, Dash PK. Enhanced catecholamine synthesis in the prefrontal cortex after traumatic brain injury: implications for prefrontal dysfunction. J Neurotrauma. 2006;23:1094&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866622</ArticleId></ArticleIdList></Reference><Reference><Citation>Birnbaum SB, Yuan P, Wang M, Vijayraghavan S, Bloom A, Davis D, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science. 2004;306:882&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15514161</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta D, Yang ST, Galvin VC, Solder J, Luo F, Morozov YM, et al. Noradrenergic &#x3b1;1-Adrenoceptor Actions in the Primate Dorsolateral Prefrontal Cortex. J Neurosci. 2019;39:2722&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6445993</ArticleId><ArticleId IdType="pubmed">30755491</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin LE, Wang M, Galvin VC, Lightbourne TC, Conn PJ, Arnsten AFT, et al. mGluR2 vs. mGluR3 in Primate Prefrontal Cortex: Postsynaptic mGluR3 Strengthen Cognitive Networks. Cereb Cortex. 2018;28:974&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5974790</ArticleId><ArticleId IdType="pubmed">28108498</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Datta D, Woo E, Duque A, Morozov YM, Arellano J, et al. Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: potential therapeutic target for neuroinflammatory cognitive disorders. Mol Psychiatry. 2022:27:4252&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9718677</ArticleId><ArticleId IdType="pubmed">35732693</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT. Through the looking glass: Differential noradrenergic modulation of prefrontal cortical function. Neural Plasticity. 2000;7:133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2565372</ArticleId><ArticleId IdType="pubmed">10709220</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta D, Leslie S, Wang M, Yang S-T, Morozov Y, Mentone S, et al. Age-related calcium dysregulation linked with tau pathology and impaired cognition in non-human primates. Alzheimer&#x2019;s Dement. 2021;17:920&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8195842</ArticleId><ArticleId IdType="pubmed">33829643</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Datta D, Del Tredici K, Braak H. Hypothesis: Tau Pathology is an Initiating Factor In Sporadic Alzheimer&#x2019;s Disease. Alzheimer&#x2019;s Dement. 2021;17:115&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7983919</ArticleId><ArticleId IdType="pubmed">33075193</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo E, Sansing LH, Arnsten AFT, Datta D. Chronic Stress Weakens Connectivity in the Prefrontal Cortex: Architectural and Molecular Changes. Chronic Stress. 2021;5:24705470211029254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8408896</ArticleId><ArticleId IdType="pubmed">34485797</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Bassam B, Thomas AG, Williams M, Liu J, Nance E, et al. Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain. Neurobiol Dis. 2016;94:116&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5394739</ArticleId><ArticleId IdType="pubmed">27326668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollinger KR, Sharma A, Tallon C, Lovell L, Thomas AG, Zhu X, et al. Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis. Nanotheranostics. 2022;6:126&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8671953</ArticleId><ArticleId IdType="pubmed">34976589</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlyle BC, Nairn AC, Wang M, Yang Y, Jin LE, Simen AA, et al. cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. Proc Natl Acad Sci USA. 2014;111:5036&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977284</ArticleId><ArticleId IdType="pubmed">24707050</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie KF, Wallace DA, Hill EV, Anthony DF, Henderson DJ, Houslay DM, et al. Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation. Biochem J. 2011;435:755&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">21323643</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Christakos S, Robinson N, Mattson MP. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. Proc Natl Acad Sci USA. 1998;95:3227&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19724</ArticleId><ArticleId IdType="pubmed">9501245</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JT, Xie XM, Yu JY, Sun YX, Liao XM, Wang XX, et al. Suppressed Calbindin Levels in Hippocampal Excitatory Neurons Mediate Stress-Induced Memory Loss. Cell Rep. 2017;21:891&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">29069596</ArticleId></ArticleIdList></Reference><Reference><Citation>Erraji-Benchekroun L, Underwood MD, Arango V, Galfalvy H, Pavlidis P, Smyrniotopoulos P, et al. Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. Biol Psychiatry. 2005;57:549&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">15737671</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Morrison JH. Neocortical neuronal subpopulations labeled by a monoclonal antibody to calbindin exhibit differential vulnerability in Alzheimer&#x2019;s disease. Exp Neurol. 1991;111:293&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">1999232</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Woo E, Yang S, Wang M, Datta D. Unusual Molecular Regulation of Dorsolateral Prefrontal Cortex Layer III Synapses Increases Vulnerability to Genetic and Environmental Insults in Schizophrenia. Biol Psychiatry. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9372235</ArticleId><ArticleId IdType="pubmed">35305820</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei H, Xie Z. Anesthesia, calcium homeostasis and Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2009;6:30&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735723</ArticleId><ArticleId IdType="pubmed">19199872</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao G, Zhang J, Zhang L, Dong Y, Yu B, Crosby G, et al. Sevoflurane induces tau phosphorylation and glycogen synthase kinase 3&#x3b2; activation in young mice. Anesthesiology. 2014;121:510&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4165789</ArticleId><ArticleId IdType="pubmed">24787352</ArticleId></ArticleIdList></Reference><Reference><Citation>Belrose JC, Noppens RR. Anesthesiology and cognitive impairment: a narrative review of current clinical literature. BMC Anesthesiol. 2019;19:241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6933922</ArticleId><ArticleId IdType="pubmed">31881996</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, Liang F, Huang L, Fang F, Yang G, Tanzi RE, et al. The anesthetic sevoflurane induces tau trafficking from neurons to microglia. Commun Biol. 2021;4:560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8115254</ArticleId><ArticleId IdType="pubmed">33980987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Huynh J, Hylin MJ, O&#x2019;Malley JJ, Perez A, Moore AN, et al. Mild Traumatic Brain Injury Reduces Spine Density of Projection Neurons in the Medial Prefrontal Cortex and Impairs Extinction of Contextual Fear Memory. J Neurotrauma. 2018;35:149&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757078</ArticleId><ArticleId IdType="pubmed">28665166</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauser H, Sahu S, Panjwani U. Guanfacine promotes neuronal survival in medial prefrontal cortex under hypobaric hypoxia. Brain Res. 2016;1636:152&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">26854138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Zhang Z, Wu L, Qiu Y, Lin Y. Suppression of Glutamate Carboxypeptidase II Ameliorates Neuronal Apoptosis from Ischemic Brain Injury. J Stroke Cerebrovasc Dis. 2016;25:1599&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068862</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong C, Zhao X, Van KC, Bzdega T, Smyth A, Zhou J, et al. NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J Neurochem. 2006;97:1015&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606367</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;cha P, Z&#xe1;mecn&#xed;k J, Barinka C, Hlouchov&#xe1; K, V&#xed;cha A, Mlcochov&#xe1; P, et al. Expression of glutamate carboxypeptidase II in human brain. Neuroscience. 2007;144:1361&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">17150306</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahn KA, Watkins CC, Alt J, Rais R, Stathis M, Grishkan I, et al. Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. Proc Natl Acad Sci USA. 2012;109:20101&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3523869</ArticleId><ArticleId IdType="pubmed">23169655</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Gao Y, Xu S, Cui Z, Zhang M, Lin Y, et al. Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury. J Neurochem. 2015;134:340&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">25872793</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Gao Y, Xu S, Bao J, Lin Y, Luo X, et al. Glutamate carboxypeptidase II gene knockout attenuates oxidative stress and cortical apoptosis after traumatic brain injury. BMC Neurosci. 2016;17:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836105</ArticleId><ArticleId IdType="pubmed">27091009</ArticleId></ArticleIdList></Reference><Reference><Citation>Neale JH, Olszewski R. A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition. Neurobiol Learn Mem. 2019;158:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6397785</ArticleId><ArticleId IdType="pubmed">30630041</ArticleId></ArticleIdList></Reference><Reference><Citation>Neale JH, Yamamoto T. N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications. Prog Neurobiol. 2020;184:101722.</Citation><ArticleIdList><ArticleId IdType="pubmed">31730793</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Hall RA, Lee M, Kamgar-Parsi A, Bi X, Baudry M. The tyrosine phosphatase PTPN13/FAP-1 links calpain-2, TBI and tau tyrosine phosphorylation. Sci Rep. 2017;7:11771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5603515</ArticleId><ArticleId IdType="pubmed">28924170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Liu Y, Nham A, Sherbaf A, Quach D, Yahya E, et al. Calpain-2 as a therapeutic target in repeated concussion-induced neuropathy and behavioral impairment. Sci Adv. 2020;6:eaba5547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7458466</ArticleId><ArticleId IdType="pubmed">32937436</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman R, Giovannone N, Hanten G, Wilde EA, McCauley SR, Hunter JV, et al. Evidence That the Blood Biomarker SNTF Predicts Brain Imaging Changes and Persistent Cognitive Dysfunction in Mild TBI Patients. Front Neurol. 2013;4:190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831148</ArticleId><ArticleId IdType="pubmed">24302918</ArticleId></ArticleIdList></Reference><Reference><Citation>Vornov JJ, Hollinger KR, Jackson PF, Wozniak KM, Farah MH, Majer P, et al. Still NAAG&#x2019;ing After All These Years: The Continuing Pursuit of GCPII Inhibitors. Adv Pharm. 2016;76:215&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">27288079</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban R, Szabo B, Starke K. Involvement of peripheral presynaptic inhibition in the reduction of sympathetic tone by moxonidine, rilmenidine and UK 14304. Eur J Pharm. 1995;282:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">7498287</ArticleId></ArticleIdList></Reference><Reference><Citation>U&#x2019;Prichard DC, Bechtel WD, Rouot BM, Snyder SH. Multiple apparent alpha-noradrenergic receptor binding sites in rat brain: effect of 6-hydroxydopamine. Mol Pharm. 1979;16:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">39248</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Goldman-Rakic PS. Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science. 1985;230:1273&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2999977</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen S, Wikberg JES. Delineation of rat kidney alpha 2A and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modeling reveals that guanfacine is an alpha-2A-selective compound. Eur J Pharm. 1991;202:235&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">1666366</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen S, Xia Y, Chhajlani V, Felder CC, Wikberg JES. [3H]MK912 binding delineates 2 a-2-adrenoceptor subtypes in rat CNS one of which is identical with the cloned pA2d a-2- adrenoceptor. Br J Pharm. 1992;106:986&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1907663</ArticleId><ArticleId IdType="pubmed">1356570</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects. J Neurosci. 1988;8:4287&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569464</ArticleId><ArticleId IdType="pubmed">2903226</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Z-M, Arnsten AFT, Li B-M. Local infusion of alpha-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol Psychiatry. 1999;46:1259&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">10560031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Tang ZX, Li BM. Enhanced visuomotor associative learning following stimulation of alpha 2A-adrenoceptors in the ventral prefrontal cortex in monkeys. Brain Res. 2004;1024:176&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos B, Stark D, Verduzco L, van Dyck CH, Arnsten AFT. Alpha-2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem. 2006;13:770&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783631</ArticleId><ArticleId IdType="pubmed">17101879</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Contant TA. Alpha-2 adrenergic agonists decrease distractability in aged monkeys performing a delayed response task. Psychopharmacology. 1992;108:159&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">1357704</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Steere JC, Hunt RD. The contribution of alpha-2 noradrenergic mechanisms to prefrontal cortical cognitive function: potential significance to Attention Deficit Hyperactivity Disorder. Arch Gen Psychiatry. 1996;53:448&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624188</ArticleId></ArticleIdList></Reference><Reference><Citation>Steere JC, Arnsten AFT. The alpha-2A noradrenergic agonist, guanfacine, improves visual object discrimination reversal performance in rhesus monkeys. Behav Neurosci. 1997;111:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9383511</ArticleId></ArticleIdList></Reference><Reference><Citation>Franowicz JCS, Arnsten AFT. The alpha-2A noradrenergic agonist, guanfacine, improves delayed response performance in young adult rhesus monkeys. Psychopharmacology. 1998;136:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9537677</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill J, Fitten LJ, Siembieda DW, Ortiz F, Halgren E. Effects of guanfacine on three forms of distraction in the aging macaque. Life Sci. 2000;67:877&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">10946847</ArticleId></ArticleIdList></Reference><Reference><Citation>Macy JDJ, Beattie TA, Morgenstern SE, Arnsten AF. Use of guanfacine to control self-injurious behavior in two rhesus macaques (Macaca mulatta) and one baboon (Papio anubis) Comp Med. 2000;50:419&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11020162</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Ji JZ, Li BM. The alpha(2A)-adrenergic agonist guanfacine improves visuomotor associative learning in monkeys. Neuropsychopharmacology. 2004;29:86&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12931141</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AFT. The alpha-2A-adenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology. 2000;23:240&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10942848</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Goldman-Rakic PS. Selective prefrontal cortical projections to the region of the locus coeruleus and raphe nuclei in the rhesus monkey. Brain Res. 1984;306:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">6466989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Wang T, Li L, Hui Y, Zhang Q, Yuan H. Activation and blockade of &#x3b1;2-adrenoceptors in the prelimbic cortex regulate anxiety-like behaviors in hemiparkinsonian rats. Biochem Biophys Res Commun. 2019;519:697&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">31542234</ArticleId></ArticleIdList></Reference><Reference><Citation>Birnbaum SG, Podell DM, Arnsten AFT. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharm Biochem Behav. 2000;67:397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hains AB, Yabe Y, Arnsten AFT. Chronic stimulation of alpha-2A-adrenoceptors with guanfacine protects rodent prefrontal cortex dendritic spines and cognition from the effects of chronic stress. Neurobiol Stress. 2015;2:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4316374</ArticleId><ArticleId IdType="pubmed">25664335</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweimer J, Fendt M, Schnitzler HU. Effects of clonidine injections into the bed nucleus of the stria terminalis on fear and anxiety behavior in rats. Eur J Pharm. 2005;507:117&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659301</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBock F, Kurz J, Azad SC, Parsons CG, Hapfelmeier G, Zieglgansberger W, et al. Alpha2-adrenoreceptor activation inhibits LTP and LTD in the basolateral amygdala: involvement of Gi/o-protein-mediated modulation of Ca2+-channels and inwardly rectifying K+-channels in LTD. Eur J Neurosci. 2003;17:1411&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">12713644</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavin SA, Matthews RT, Wang Q, Muly EC, Winder DG. &#x3b1;(2A)-adrenergic receptors filter parabrachial inputs to the bed nucleus of the stria terminalis. J Neurosci. 2014;34:9319&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087209</ArticleId><ArticleId IdType="pubmed">25009265</ArticleId></ArticleIdList></Reference><Reference><Citation>Mineur YS, Cahuzac EL, Mose TN, Bentham MP, Plantenga ME, Thompson DC, et al. Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety- and depression-related behaviors in mice. Neuropsychopharmacology. 2018;43:2118&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6098039</ArticleId><ArticleId IdType="pubmed">29472646</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentino RJ, Curtis AL, Page ME, Pavcovich LA, Florin-Lechner SM. Activation of the locus coeruleus brain noradrenergic system during stress: Circuitry, consequences, and regulation. Adv Pharm. 1998;42:781&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9328014</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Aghajanian GK. Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur J Pharm. 1977;44:375&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">330174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida Y, Elsworth J, Roth RH. Anxiogenic beta carboline FG7142 produces activation of NE neurons in specific brain regions of rats. Pharm Biochem Behav. 1991;39:791&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">1784607</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow BA, George TP, Roth RH. Noradrenergic alpha-2 agonists have anxiolytic-like actions on stress-related behavior and mesoprefrontal dopamine biochemistry. Brain Res. 2004;1027:173&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494168</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelps EA, LeDoux JE. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron. 2005;48:175&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242399</ArticleId></ArticleIdList></Reference><Reference><Citation>Roozendaal B, McGaugh JL. Memory modulation. Behav Neurosci. 2011;125:797&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236701</ArticleId><ArticleId IdType="pubmed">22122145</ArticleId></ArticleIdList></Reference><Reference><Citation>Engberg G, Eriksson E. Effects of alpha-2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in EEDQ-treated rats. Naunyn-Schmiedebergs Arch Pharm. 1991;343:472&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1652697</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuyama K, Nakano T, Shiroyama T, Okada M. Chronic Administrations of Guanfacine on Mesocortical Catecholaminergic and Thalamocortical Glutamatergic Transmissions. Int J Mol Sci. 2021;22:4122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8073983</ArticleId><ArticleId IdType="pubmed">33923533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballesteros JJ, Briscoe JB, Ishizawa Y. Neural signatures of &#x3b1;2-Adrenergic agonist-induced unconsciousness and awakening by antagonist. Elife. 2020;9:e57670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455241</ArticleId><ArticleId IdType="pubmed">32857037</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology. 2003;98:428&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">12552203</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansson CC, Pohjanoksa K, Lang J, Wurster S, Savola JM, Scheinin M. Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. Eur J Pharm. 1999;374:137&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10422650</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzsaki G, Kennedy B, Solt VB, Ziegler M. Noradrenergic control of thalamic oscillation: The role of alpha-2 receptors. Eur J Neuro. 1991;3:222&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12106199</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholas AP, Pieribone V, H&#xf6;kfelt T. Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol. 1993;328:575&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8381444</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald E, Scheinin M. Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system. J Physiol Pharm. 1995;46:241&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">8527807</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, He J, Yu N, Jia C, Wang S. Mechanisms of Dexmedetomidine in Neuropathic Pain. Front Neurosci. 2020;14:330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7214625</ArticleId><ArticleId IdType="pubmed">32431587</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahari Z, Meftahi GH. Spinal &#x3b1;2 -adrenoceptors and neuropathic pain modulation; therapeutic target. Br J Pharm. 2019;176:2366&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6592871</ArticleId><ArticleId IdType="pubmed">30657594</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BM, Jang Y, Park G, Kim K, Oh SH, Shin TJ, et al. Dexmedetomidine modulates transient receptor potential vanilloid subtype 1. Biochem Biophys Res Commun. 2020;522:832&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31796207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao JW, Qiao WL, Li Q, Wei S, Liu TT, Qiu CY, et al. Suppression of P2X3 receptor-mediated currents by the activation of &#x3b1;2A -adrenergic receptors in rat dorsal root ganglion neurons. CNS Neurosci Ther. 2022;28:289&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8739037</ArticleId><ArticleId IdType="pubmed">34862748</ArticleId></ArticleIdList></Reference><Reference><Citation>Farghaly HS, Mahmoud AM, Abdel-Sater KA. Effect of dexmedetomidine and cold stress in a rat model of neuropathic pain: Role of interleukin-6 and tumor necrosis factor-&#x3b1;. Eur J Pharm. 2016;776:139&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">26896779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer KK, Mitri&#x107; M, Kalpachidou T, Kress M. The Medial Prefrontal Cortex as a Central Hub for Mental Comorbidities Associated with Chronic Pain. Int J Mol Sci. 2020;21:3440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7279227</ArticleId><ArticleId IdType="pubmed">32414089</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Wang TJ, Wang G, Yang M, Zhou Y, Yuan Y. Effects of Dexmedetomidine on Postoperative Delirium and Expression of IL-1&#x3b2;, IL-6, and TNF-&#x3b1; in Elderly Patients After Hip Fracture Operation. Front Pharm. 2020;11:678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235357</ArticleId><ArticleId IdType="pubmed">32477139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Kang Z, Wang Y, Zhao J, Li S. The Anti-inflammatory Effect of Dexmedetomidine Administration on Patients Undergoing Intestinal Surgery: A Randomized Study. Drugs R D. 2021;21:445&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8602546</ArticleId><ArticleId IdType="pubmed">34750767</ArticleId></ArticleIdList></Reference><Reference><Citation>Lankadeva YR, Shehabi Y, Deane AM, Plummer MP, Bellomo R, May CN. Emerging benefits and drawbacks of &#x3b1;2 -adrenoceptor agonists in the management of sepsis and critical illness. Br J Pharm. 2021;178:1407&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33450087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding M, Xu X, Xia L, Cao Y. Magnetic Resonance Imaging Characteristic Evaluation of Dexmedetomidine on Neurocognitive Dysfunction in Elderly Patients with Colorectal Tumors after Laparoscopic Operation. Comput Math Methods Med. 2022;2022:1345695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9256310</ArticleId><ArticleId IdType="pubmed">35799659</ArticleId></ArticleIdList></Reference><Reference><Citation>Scanzano A, Cosentino M. Adrenergic regulation of innate immunity: a review. Front Pharm. 2015;6:171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4534859</ArticleId><ArticleId IdType="pubmed">26321956</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y, Huang X, Liu Z, Han G, Huang L, Xiong YC, et al. Dexmedetomidine inhibits the secretion of high mobility group box 1 from lipopolysaccharide-activated macrophages in vitro. J Surg Res. 2013;181:308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">22939552</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto M, Higuchi H, Honda-Wakasugi Y, Miyake S, Nishioka Y, Yabuki-Kawase A, et al. Dexmedetomidine inhibits LPS-induced inflammatory responses through peroxisome proliferator-activated receptor gamma (PPAR&#x3b3;) activation following binding to &#x3b1;2 adrenoceptors. Eur J Pharm. 2021;892:173733.</Citation><ArticleIdList><ArticleId IdType="pubmed">33220278</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyoneva S, Traynelis SF. Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors. J Biol Chem. 2013;288:15291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3663549</ArticleId><ArticleId IdType="pubmed">23548902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kii N, Sawada A, Yoshikawa Y, Tachibana S, Yamakage M. Dexmedetomidine Ameliorates Perioperative Neurocognitive Disorders by Suppressing Monocyte-Derived Macrophages in Mice With Preexisting Traumatic Brain Injury. Anesth Analg. 2022;134:869&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">34319918</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Ma W, Zhu J, Jiao W, Wang Y. Dexmedetomidine alleviates early brain injury following traumatic brain injury by inhibiting autophagy and neuroinflammation through the ROS/Nrf2 signaling pathway. Mol Med Rep. 2021;24:661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8335733</ArticleId><ArticleId IdType="pubmed">34278508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Y, B&#xf6;hmer T, Jiang S, Gericke A. The role of adrenoceptors in the retina. Cells. 2020;9:2594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7761662</ArticleId><ArticleId IdType="pubmed">33287335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota T, Yamamuro K, Okazaki K, Kishimoto T. Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy. Drug Des Devel Ther. 2021;15:1965&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8123957</ArticleId><ArticleId IdType="pubmed">34007156</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor DF, Grasso DJ, Slivinsky MD, Pearson GS, Banga A. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents. J Child Adolesc Psychopharmacol. 2013;23:244&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657282</ArticleId><ArticleId IdType="pubmed">23683139</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor DF, Findling RL, Kollins SH, Sallee F, L&#xf3;pez FA, Lyne A, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24:755&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">20806988</ArticleId></ArticleIdList></Reference><Reference><Citation>McCracken JT, Aman MG, McDougle CJ, Tierney E, Shiraga S, Whelan F, et al. Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. J Child Adolesc Psychopharmacol. 2010;20:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2835389</ArticleId><ArticleId IdType="pubmed">20166790</ArticleId></ArticleIdList></Reference><Reference><Citation>Politte LC, Scahill L, Figueroa J, McCracken JT, King B, McDougle CJ. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology. 2018;43:1772&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6006142</ArticleId><ArticleId IdType="pubmed">29540864</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, Wakimoto Y, Filangieri C, Pinkhasov A, Angulo M. Guanfacine Extended Release for the Reduction of Aggression, Attention-Deficit/Hyperactivity Disorder Symptoms, and Self-Injurious Behavior in Prader-Willi Syndrome-A Retrospective Cohort Study. J Child Adolesc Psychopharmacol. 2019;29:313&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30724590</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman ZT, Rice KA, Soto PL, Pate KA, Weed MR, Ator NA, et al. Neurocognitive dysfunction and pharmacological intervention using guanfacine in a rhesus macaque model of self-injurious behavior. Transl Psychiatry. 2015;5:e567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4471292</ArticleId><ArticleId IdType="pubmed">25989141</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllister TW, McDonald BC, Flashman LA, Ferrell RB, Tosteson TD, Yanofsky NN, et al. Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: Altered working memory and BOLD response. Int J Psychophysiol. 2011;82:107&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3210922</ArticleId><ArticleId IdType="pubmed">21767584</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra PA, Parton AD, Greenwood R, Husain M. Noradrenergic modulation of space exploration in visual neglect. Ann Neurol. 2006;59:186&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16261567</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalmaijer ES, Li KMS, Gorgoraptis N, Leff AP, Cohen DL, Parton AD, et al. Randomised, double-blind, placebo-controlled crossover study of single-dose guanfacine in unilateral neglect following stroke. J Neurol Neurosurg Psychiatry. 2018;89:593&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6031270</ArticleId><ArticleId IdType="pubmed">29436486</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh-Curry V, Malhotra P, Farmer SF, Husain M. Attention deficits following ADEM ameliorated by guanfacine. J Neurol Neurosurg Psychiatry. 2011;82:688&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090126</ArticleId><ArticleId IdType="pubmed">20562462</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesharaki-Zadeh A, Lowe N, Arnsten AFT. Clinical experience with the &#x3b1;2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in &#x201c;Long-COVID19&#x201d;. Neuroimmunol Rep. 2023;3:100154.</Citation></Reference><Reference><Citation>Hoang K, Watt H, Golemme M, Perry RJ, Ritchie C, Wilson D, et al. Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer&#x2019;s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments. Trials. 2022;23:623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9340683</ArticleId><ArticleId IdType="pubmed">35915506</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298:2644&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18073360</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer SC, Moral F, Preloger E, Spindler A, Roman M, Logan A, et al. Pediatric COVID-19 Delirium: Case Report of 2 Adolescents. WMJ. 2021;120:131&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">34255953</ArticleId></ArticleIdList></Reference><Reference><Citation>Srour H, Pandya K, Flannery A, Hatton K. Enteral Guanfacine to Treat Severe Anxiety and Agitation Complicating Critical Care After Cardiac Surgery. Semin Cardiothorac Vasc Anesth. 2018;22:403&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29619866</ArticleId></ArticleIdList></Reference><Reference><Citation>Sher Y, Rabkin B, Maldonado JR, Mohabir P. COVID-19-Associated Hyperactive Intensive Care Unit Delirium With Proposed Pathophysiology and Treatment: A Case Report. Psychosomatics. 2020;61:544&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236743</ArticleId><ArticleId IdType="pubmed">32591212</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, Czuma R, Cohen-Oram A, Hartney K, Stern TA. Guanfacine for Hyperactive Delirium: A Case Series. J Acad Consult Liaison Psychiatry. 2021;62:83&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">33272699</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>